Literature DB >> 23649330

Recent advances in claudin-targeting technology.

Shotaro Nagase1, Ryo Doyama, Kiyohito Yagi, Masuo Kondoh.   

Abstract

Most malignant tumors are derived from epithelium, and pathologic microorganisms often invade the body through the mucosal epithelium. Thus epithelial tissues are potent targets for drug delivery. The tight junction (TJ) is the intercellular seal in epithelial cell sheets. Claudins (CLs) are a family of tetratransmembrane proteins with a molecular mass of approximately 23 kDa. CLs are key structural and sealing components of TJs. CLs are often overexpressed in malignant tumors. CL-4 is highly expressed in the epithelial cells covering mucosal immune tissues. Therefore CLs may be potent targets for drug delivery, cancer therapy, and mucosal vaccination. Herein, we overview a series of our studies using the C-terminal fragment of Clostridium perfringens enterotoxin to target and bind CLs; we also discuss the efficacy of CL-targeted drug delivery.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23649330     DOI: 10.1248/bpb.b13-00014

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  5 in total

Review 1.  Systems Proteomics View of the Endogenous Human Claudin Protein Family.

Authors:  Fei Liu; Michael Koval; Shoba Ranganathan; Susan Fanayan; William S Hancock; Emma K Lundberg; Ronald C Beavis; Lydie Lane; Paula Duek; Leon McQuade; Neil L Kelleher; Mark S Baker
Journal:  J Proteome Res       Date:  2016-01-12       Impact factor: 4.466

Review 2.  Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.

Authors:  Shujing Wang; Huiqin Liu; Xinyi Zhang; Feng Qian
Journal:  Protein Cell       Date:  2015-05-06       Impact factor: 14.870

3.  Low claudin-6 expression correlates with poor prognosis in patients with non-small cell lung cancer.

Authors:  Qiang Wang; Yan Zhang; Tao Zhang; Zhi-Gang Han; Li Shan
Journal:  Onco Targets Ther       Date:  2015-07-31       Impact factor: 4.147

4.  Efficacy and safety evaluation of claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibody.

Authors:  Yosuke Hashimoto; Yumi Kawahigashi; Tomoyuki Hata; Xiangru Li; Akihiro Watari; Minoru Tada; Akiko Ishii-Watabe; Yoshiaki Okada; Takefumi Doi; Masayoshi Fukasawa; Hiroki Kuniyasu; Kiyohito Yagi; Masuo Kondoh
Journal:  Pharmacol Res Perspect       Date:  2016-09-27

5.  Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting.

Authors:  Hobin Yang; Hayeon Park; Yong Jin Lee; Jun Young Choi; TaeEun Kim; Nirmal Rajasekaran; Saehyung Lee; Kyoung Song; Sungyoul Hong; Joon-Seok Choi; Hyunbo Shim; Young-Deug Kim; Soohyun Hwang; Yoon-La Choi; Young Kee Shin
Journal:  Biomolecules       Date:  2019-12-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.